Pembrolizumab + Irinotecan + Paclitaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Conditions
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Trial Timeline
Jun 20, 2017 → Oct 31, 2021
NCT ID
NCT03136055About Pembrolizumab + Irinotecan + Paclitaxel
Pembrolizumab + Irinotecan + Paclitaxel is a phase 2 stage product being developed by Merck for High Grade Malignant Neuroendocrine Carcinoma (Diagnosis). The current trial status is completed. This product is registered under clinical trial identifier NCT03136055. Target conditions include High Grade Malignant Neuroendocrine Carcinoma (Diagnosis).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03136055 | Phase 2 | Completed |
Competing Products
20 competing products in High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)